- Home
- NIVF vs PSTV Comparison
NIVF vs PSTV Comparison
Compare NIVF & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- PSTV
- Stock Information
- Founded
- NIVF 2011
- PSTV 1996
- Country
- NIVF Hong Kong
- PSTV United States
- Employees
- NIVF N/A
- PSTV N/A
- Industry
- NIVF
- PSTV Medical/Dental Instruments
- Sector
- NIVF
- PSTV Health Care
- Exchange
- NIVF NYSE
- PSTV Nasdaq
- Market Cap
- NIVF 2.1M
- PSTV 12.2M
- IPO Year
- NIVF N/A
- PSTV N/A
- Fundamental
- Price
- NIVF $3.38
- PSTV $0.66
- Analyst Decision
- NIVF
- PSTV Strong Buy
- Analyst Count
- NIVF 0
- PSTV 3
- Target Price
- NIVF N/A
- PSTV $12.75
- AVG Volume (30 Days)
- NIVF 351.5K
- PSTV 3.6M
- Earning Date
- NIVF 01-01-0001
- PSTV 05-19-2025
- Dividend Yield
- NIVF N/A
- PSTV N/A
- EPS Growth
- NIVF N/A
- PSTV N/A
- EPS
- NIVF N/A
- PSTV N/A
- Revenue
- NIVF $5,433,375.00
- PSTV $5,824,000.00
- Revenue This Year
- NIVF N/A
- PSTV $13.26
- Revenue Next Year
- NIVF N/A
- PSTV $8.84
- P/E Ratio
- NIVF N/A
- PSTV N/A
- Revenue Growth
- NIVF 5.79
- PSTV 18.54
- 52 Week Low
- NIVF $1.09
- PSTV $0.24
- 52 Week High
- NIVF $32.80
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- NIVF 40.15
- PSTV 45.72
- Support Level
- NIVF $2.82
- PSTV $0.49
- Resistance Level
- NIVF $4.96
- PSTV $0.90
- Average True Range (ATR)
- NIVF 0.80
- PSTV 0.13
- MACD
- NIVF 0.30
- PSTV -0.00
- Stochastic Oscillator
- NIVF 33.61
- PSTV 23.29
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).